Fariborz Kamal
President bij 4D MOLECULAR THERAPEUTICS, INC.
Vermogen: 189 312 $ op 31-03-2024
Profiel
Fariborz Kamal is currently the President & Chief Operating Officer at 4D Molecular Therapeutics, Inc. He previously held positions as Vice President-Quality & Regulatory CMC at InterMune, Inc. from 2013 to 2015, Vice President-Quality at Juno Therapeutics, Inc. from 2015 to 2017, and Senior Vice President-Quality & Regulatory CMC at Novartis Gene Therapies, Inc. from 2017 to 2018.
Dr. Kamal obtained his graduate and doctorate degrees from American University in 2000 and 2003 respectively, and his undergraduate degree from San Jose State University in 1986.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 11-12-2023 | 5 942 ( 0.01% ) | 189 312 $ | 31-03-2024 |
Actieve functies van Fariborz Kamal
| Bedrijven | Functie | Begin |
|---|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | President | 23-09-2022 |
Eerdere bekende functies van Fariborz Kamal
| Bedrijven | Functie | Einde |
|---|---|---|
| AVEXIS INC | Corporate Officer/Principal | 01-08-2018 |
| JUNO THERAPEUTICS INC | Corporate Officer/Principal | 01-04-2017 |
| INTERMUNE INC | Corporate Officer/Principal | 01-03-2015 |
Opleiding van Fariborz Kamal
| American University | Doctorate Degree |
| San Jose State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
